Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)
about
Barriers to a cure for HIV in womenPreventing HIV infection: pre-exposure and postexposure prophylaxisDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Current perspectives in HIV post-exposure prophylaxis.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesThe use of preexposure treatments for HIV prophylaxisPharmacokinetics of antiretrovirals in mucosal tissueRelationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Antiretroviral bioanalysis methods of tissues and body biofluids.Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.Role of raltegravir in HIV-1 management.Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
P2860
Q26768632-25EDAAE6-2B84-4742-B63C-99A8FD37841AQ26828445-24EC5AC9-8636-487E-BED9-A8E81EB33516Q28081272-606106DF-4462-4B53-944D-3FA18C95F6F5Q30431343-8D1ED403-134E-4344-926B-778E384A39EBQ33686465-0F0652C4-EB06-48CA-954D-1A7955B41738Q33798045-BBA2356D-B58C-452C-A1C7-46186A16CE97Q33888718-C36B2711-EBAD-42FB-867C-88F52CDAC5D7Q34434815-E882D149-AD7D-41D0-94A7-A42A0E817E39Q35432739-5ADD749B-E96E-4B6E-A122-D868523054C0Q35760180-DDBF0E05-E10C-4A14-892B-12A9446B159CQ35838594-9C042602-268C-42C9-B26F-48B7F3C22188Q36078470-B919450D-B2BD-46F8-8B9E-F05E38D590C1Q36086387-8510F5DD-D47D-44B0-84D9-58062B716DFAQ36442232-79C60905-1DDF-49E8-B47A-587F95D25A31Q36887876-32F9E23D-AA95-48D2-A2F9-F8CC9DA25E49Q36901505-F740EFAC-82E6-427E-8A78-C4CDD5750D4AQ37332868-C861C540-87D1-4070-AF2D-B59CC414031FQ37592039-1BF86CF0-FDD8-48F3-AEEB-B649793E9DA5Q38002011-C1830621-D88A-4D6E-AB72-9979E722A7ACQ38527537-B873CE8B-93A1-4BFD-9A0A-2F28A35DD8ACQ40103140-2D82F004-73BB-45A9-9245-CFA156CA12A4Q47624840-D03844F0-D672-4463-96A6-66A0BDA13CE4
P2860
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Raltegravir concentrations in ...... aining regimen (DIVA 01 study)
@ast
Raltegravir concentrations in ...... aining regimen (DIVA 01 study)
@en
type
label
Raltegravir concentrations in ...... aining regimen (DIVA 01 study)
@ast
Raltegravir concentrations in ...... aining regimen (DIVA 01 study)
@en
prefLabel
Raltegravir concentrations in ...... aining regimen (DIVA 01 study)
@ast
Raltegravir concentrations in ...... aining regimen (DIVA 01 study)
@en
P2093
P2860
P50
P356
P1476
Raltegravir concentrations in ...... aining regimen (DIVA 01 study)
@en
P2093
Anne-Geneviève Marcelin
Catherine Crenn-Hebert
Cathia Soulié
Claudia Ferreira
Cyril Clavel
François Bissuel
Houria Ichou
Isabelle Heard
Laurent Mandelbrot
Roland Tubiana
P2860
P304
P356
10.1128/AAC.01460-10
P407
P577
2011-03-28T00:00:00Z